• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

门静脉栓塞与钇-90 微球放射肝段切除术治疗初始不可切除肝细胞癌的对比研究。

A comparative study of portal vein embolization versus radiation lobectomy with Yttrium-90 micropheres in preparation for liver resection for initially unresectable hepatocellular carcinoma.

机构信息

Recanati-Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, NY.

Department of Surgery, Centre Médico-Chirurgical de Tronquières, Aurillac, France.

出版信息

Surgery. 2021 May;169(5):1044-1051. doi: 10.1016/j.surg.2020.12.012. Epub 2021 Feb 27.

DOI:10.1016/j.surg.2020.12.012
PMID:33648768
Abstract

BACKGROUND

Portal vein embolization before liver resection is considered the therapy of choice for patients with inadequate future liver remnants. The concept of radioembolization with Yttrium-90 to achieve the same goal has limited data.

METHODS

We retrospectively compared patients who underwent portal vein embolization and Yttrium-90 lobectomy before resection of hepatocellular carcinoma in patients with chronic liver disease.

RESULTS

Seventy-three patients underwent portal vein embolization and 22 patients underwent Yttrium-90. Forty-seven percent of patients before portal vein embolization required additional procedures for tumor control, and 27% of patients after Yttrium-90 required additional procedure to mainly induce further hypertrophy. Both therapies achieved the goal of future liver remnants >40%, but the degree of hypertrophy was significantly higher in Yttrium-90 patients (63% for Yttrium-90, 36% for portal vein embolization, P < .01). Tumor response was significantly better with Yttrium-90, achieving complete response in 50% of patients. Resectability rate was higher after portal vein embolization (85% for portal vein embolization, 64% for Yttrium-90, P = .03). Tumor progression was the most common reason precluding surgery. Complete tumor control was the reason not to pursue surgery in 18% of patients after Yttrium-90.

CONCLUSION

Both preoperative portal vein embolization and Yttrium-90, increases liver resectability rates by inducing hypertrophy of future liver remnants in patients with hepatocellular carcinoma and chronic liver disease. Yttrium-90 lobectomy achieved better tumor control and provided more time to assess therapy response, optimizing the indication for surgery.

摘要

背景

在进行肝脏切除术前进行门静脉栓塞术被认为是未来肝残存量不足患者的首选治疗方法。钇-90 放射性栓塞术实现相同目标的概念数据有限。

方法

我们回顾性比较了慢性肝病患者行肝癌切除术前行门静脉栓塞术和钇-90 叶切除术的患者。

结果

73 例患者行门静脉栓塞术,22 例患者行钇-90 叶切除术。门静脉栓塞术前 47%的患者需要进行额外的肿瘤控制手术,而 27%的患者在接受钇-90 治疗后需要进行额外的手术以主要诱导进一步的肝肿大。两种治疗方法都达到了未来肝残存量>40%的目标,但钇-90 患者的肝肿大程度明显更高(钇-90 为 63%,门静脉栓塞术为 36%,P<.01)。钇-90 的肿瘤反应明显更好,50%的患者达到完全缓解。门静脉栓塞术后的可切除率更高(门静脉栓塞术为 85%,钇-90 为 64%,P=.03)。肿瘤进展是最常见的手术禁忌原因。18%的患者在接受钇-90 治疗后,完全肿瘤控制是不进行手术的原因。

结论

术前门静脉栓塞术和钇-90 均可通过诱导肝癌和慢性肝病患者未来肝残存量的肝肿大来提高肝切除率。钇-90 叶切除术实现了更好的肿瘤控制,并提供了更多的时间来评估治疗反应,从而优化了手术适应证。

相似文献

1
A comparative study of portal vein embolization versus radiation lobectomy with Yttrium-90 micropheres in preparation for liver resection for initially unresectable hepatocellular carcinoma.门静脉栓塞与钇-90 微球放射肝段切除术治疗初始不可切除肝细胞癌的对比研究。
Surgery. 2021 May;169(5):1044-1051. doi: 10.1016/j.surg.2020.12.012. Epub 2021 Feb 27.
2
Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection.放射叶切除术:不可切除肝癌作为切除桥接的未来剩余肝脏体积的时间依赖性分析。
J Hepatol. 2013 Nov;59(5):1029-36. doi: 10.1016/j.jhep.2013.06.015. Epub 2013 Jun 25.
3
Outcomes of Surgical Resection after Radioembolization for Hepatocellular Carcinoma.肝细胞癌经动脉放射性栓塞治疗后手术切除的疗效
J Vasc Interv Radiol. 2018 Nov;29(11):1502-1510.e1. doi: 10.1016/j.jvir.2018.06.027. Epub 2018 Sep 27.
4
Preoperative selective portal vein embolization (PSPVE) before major hepatic resection. Effectiveness of Doppler estimation of hepatic blood flow to predict the hypertrophy rate of non-embolized liver segments.肝大部切除术前的选择性门静脉栓塞术(PSPVE)。利用多普勒估计肝血流以预测未栓塞肝段肥大率的有效性。
Hepatogastroenterology. 2002 Sep-Oct;49(47):1405-11.
5
Volumetric changes after (90)y radioembolization for hepatocellular carcinoma in cirrhosis: an option to portal vein embolization in a preoperative setting?肝硬化患者经 90y 放射性栓塞治疗肝癌后体积变化:术前门静脉栓塞术的一种选择?
Ann Surg Oncol. 2013 Aug;20(8):2518-25. doi: 10.1245/s10434-013-2906-9. Epub 2013 Mar 15.
6
Neoadjuvant Radiation Lobectomy As an Alternative to Portal Vein Embolization in Hepatocellular Carcinoma.新辅助放疗左半肝切除术在肝细胞癌中的应用。
Semin Nucl Med. 2019 May;49(3):197-203. doi: 10.1053/j.semnuclmed.2019.01.009. Epub 2019 Feb 7.
7
Impact of split completeness on future liver remnant hypertrophy in associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) in hepatocellular carcinoma: Complete-ALPPS versus partial-ALPPS.在肝细胞癌的联合肝脏离断和门静脉结扎分期肝切除术(ALPPS)中,分割完整性对未来肝剩余体积增大的影响:完全性ALPPS与部分性ALPPS对比
Surgery. 2017 Feb;161(2):357-364. doi: 10.1016/j.surg.2016.07.029. Epub 2016 Sep 3.
8
A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.一种估算钇-90玻璃基放射性栓塞治疗后肝细胞癌所接受剂量的简单方法:概念验证研究的初步结果
J Vasc Interv Radiol. 2014 Feb;25(2):277-87. doi: 10.1016/j.jvir.2013.11.007.
9
Transhepatic ipsilateral right portal vein embolization extended to segment IV: improving hypertrophy and resection outcomes with spherical particles and coils.经肝同侧右门静脉栓塞扩展至IV段:使用球形颗粒和线圈改善肥大及切除效果
J Vasc Interv Radiol. 2005 Feb;16(2 Pt 1):215-25. doi: 10.1097/01.RVI.0000147067.79223.85.
10
Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres.放射性栓塞治疗伴门静脉侵犯的肝细胞癌的疗效:树脂微球与玻璃微球对比
J Vasc Interv Radiol. 2016 Jun;27(6):812-821.e2. doi: 10.1016/j.jvir.2016.01.147. Epub 2016 Apr 7.

引用本文的文献

1
Augmenting the Future Liver Remnant Prior to Major Hepatectomy: A Review of Options on the Menu.肝大部切除术前增加未来肝残余量:可选方法综述
Ann Surg Oncol. 2025 Jun 8. doi: 10.1245/s10434-025-17607-z.
2
Selective internal radiation therapy across Barcelona Clinic Liver Cancer (BCLC) stages of hepatocellular carcinoma: literature review.肝细胞癌巴塞罗那临床肝癌(BCLC)各阶段的选择性内放射治疗:文献综述
Hepatobiliary Surg Nutr. 2024 Dec 1;13(6):974-990. doi: 10.21037/hbsn-23-504. Epub 2024 Jun 6.
3
Sequential Y liver radioembolization and portal vein embolization: an additional strategy to downstage liver tumors and to enhance liver hypertrophy before major hepatectomies.
序贯 Y 型肝脏放射性栓塞和门静脉栓塞:在大肝切除术前降期肝脏肿瘤和增强肝脏肥大的附加策略。
Langenbecks Arch Surg. 2023 Aug 28;408(1):339. doi: 10.1007/s00423-023-03083-0.
4
Dose finding study for unilobar radioembolization using holmium-166 microspheres to improve resectability in patients with HCC: the RALLY protocol.钬-166 微球单叶放射性栓塞剂量研究:提高 HCC 患者可切除性的 RALLY 方案。
BMC Cancer. 2023 Aug 18;23(1):771. doi: 10.1186/s12885-023-11280-9.
5
Yttrium-90 Radioembolization: Current Indications and Outcomes.钇-90 放射性栓塞术:当前适应证和结局。
J Gastrointest Surg. 2023 Mar;27(3):604-614. doi: 10.1007/s11605-022-05559-8. Epub 2022 Dec 22.
6
Transarterial chemoembolization failure/refractoriness: A scientific concept or pseudo-proposition.经动脉化疗栓塞失败/难治性:一个科学概念还是伪命题。
World J Gastrointest Surg. 2022 Jun 27;14(6):528-537. doi: 10.4240/wjgs.v14.i6.528.
7
Role of interventional oncology in hepatocellular carcinoma: Future best practice beyond current guidelines.介入肿瘤学在肝细胞癌中的作用:超越当前指南的未来最佳实践。
Br J Radiol. 2022 Sep 1;95(1138):20220379. doi: 10.1259/bjr.20220379. Epub 2022 Aug 4.
8
The impact of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) on liver tumors with unusual indications.联合肝脏分隔和门静脉结扎的分期肝切除术(ALPPS)对具有特殊适应证的肝肿瘤的影响。
Hepatobiliary Surg Nutr. 2022 Jun;11(3):477-480. doi: 10.21037/hbsn-2022-11.
9
Imaging-guided interventions modulating portal venous flow: Evidence and controversies.影像引导下调节门静脉血流的干预措施:证据与争议
JHEP Rep. 2022 Apr 4;4(7):100484. doi: 10.1016/j.jhepr.2022.100484. eCollection 2022 Jul.
10
TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLC.肝癌 TARE:从 BCLC 的右侧到左侧。
Cardiovasc Intervent Radiol. 2022 Nov;45(11):1599-1607. doi: 10.1007/s00270-022-03072-8. Epub 2022 Feb 11.